SecBot SecBot
8-K ·Filed May 7, 2026

ZLAB

Zai Lab Ltd
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001628280-26-031624
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The 10% product revenue decline and widening net loss are the headline numbers, the stock will likely trade down on the miss vs consensus. However, the zoci pipeline data (62.5% iORR) and KarXT launch catalyst provide a floor. Watch for: (1) ZEJULA stabilization trajectory, (2) KarXT launch metrics in Q2, (3) TIVDAK NMPA decision timeline, and (4) zoci registrational study enrollment updates. The $761M cash runway supports the pipeline thesis but the commercial headwinds are real.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$19.77
T+0 close · May 7, 2026 · via day close
Latest settled
−8.02%
T+60 · $18.18
Vs SPY
−11.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $19.77entry
  2. T+1 · 6mo ago −5.89%α −6.72% · $18.60
  3. T+5 · 6mo ago +3.57%α +2.06% · $20.47
  4. T+20 · 6mo ago −13.13%α −16.27% · $17.17
  5. T+60 · 4mo ago −8.02%α −11.85% · $18.18

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zai Lab reported Q1 2026 total revenue of $99.6M, down 6% YoY from $106.5M, and product revenue of $95.6M, down 10% YoY. Net loss widened to $51.0M ($0.05 per share) from $48.4M ($0.04 per share) in Q1 2025, driven by lower ZEJULA sales due to generic competition and higher R&D spend. The decline in headline revenue and widening loss is partially offset by strong pipeline progress (zoci AACR data, KarXT launch prep, positive partner readouts for povetacicept and elegrobart), but the near-term financial trajectory is negative.

Key Financial Metrics

EPS
−$0.05
est −$0.58 · +91.4%
Revenue
$99.6M
est $108.4M · -8.1% · -6.5% YoY
Rating
miss

Key Facts

  • Total revenue $99.6M in Q1 2026, down 6% YoY from $106.5M
  • Product revenue $95.6M, down 10% YoY (12% at CER)
  • ZEJULA sales fell to $30.0M from $49.5M (-39% YoY) due to generic olaparib competition
  • Net loss widened to $51.0M ($0.05 per share) from $48.4M ($0.04 per share)
  • R&D expenses increased to $65.6M from $60.7M (+8% YoY)
  • Cash and investments totaled $761.3M, down from $789.6M at year-end 2025
  • XACDURO grew to $8.6M from $1.1M (+682% YoY); NUZYRA grew to $16.3M from $15.1M (+8% YoY)
  • zoci showed 62.5% intracranial ORR at AACR; collaborations with Amgen and Boehringer Ingelheim announced
  • KarXT launch preparations underway in China; TIVDAK under NMPA review
  • Positive Phase 3 readouts for partner programs povetacicept (IgAN) and elegrobart (TED)

Financial Impact

Revenue decline of $6.9M YoY; net loss increase of $2.6M YoY; ZEJULA franchise decline of $19.5M YoY

revenuenet lossproduct revenueZEJULA salesR&D expenses

Risk Factors

  • ZEJULA erosion accelerating from generic olaparib VBP in China
  • VYVGART NRDL pricing adjustment may continue to pressure sales
  • KarXT launch execution risk in China
  • R&D spend increasing without near-term revenue offset
  • Cash burn rate of ~$28M/quarter may accelerate

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-031624
Document: zlab-20260507.htm0001628280-26-031624
Document: 0001628280-26-031624-index-headers.html0001628280-26-031624
Document: 0001628280-26-031624-index.html0001628280-26-031624
Document: 0001628280-26-031624.txt0001628280-26-031624
8-K Data (Synthetic)0001628280-26-031624

Track record

23 reports on ZLAB

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +3.35% at T+20 after the May 19, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  2. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $22.60 to $25.48 Now $23.47 +3.85% ▲ +12.74% +12.43% vs SPY
  3. Oct 23, 202624d ago 8-K Bullish 6/10 Entry $24.03 to $24.34 Now $23.47 −2.33% ▲ +1.29% +0.58% vs SPY
  4. Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $25.64 to $26.17 Now $23.47 −8.46% ▲ +2.07% +1.75% vs SPY
  5. Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
  6. Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
  7. Aug 12, 202613w ago 144 Neutral 2/10 Entry $25.49 to $26.03 Now $23.47 −7.92% ▲ +2.12% +1.42% vs SPY
  8. Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $19.12 to $19.08 Now $23.47 +22.75% ▼ −0.21% −1.08% vs SPY
  9. Jun 29, 202620w ago Insider Cluster Neutral 3/10 Entry $19.00 to $19.15 Now $23.47 +23.53% ▲ +0.79% +0.92% vs SPY
  10. Jun 11, 202622w ago Institutional Cluster Bearish 5/10 Entry $17.64 to $17.07 Now $23.47 −33.05% ▲ +3.23% +3.77% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 23m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026